Skip to main content
Top
Published in: Critical Care 4/2012

Open Access 01-08-2012 | Research

Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study

Authors: Nicolas Mongardon, Adeline Max, Adrien Bouglé, Frédéric Pène, Virginie Lemiale, Julien Charpentier, Alain Cariou, Jean-Daniel Chiche, Jean-Pierre Bedos, Jean-Paul Mira

Published in: Critical Care | Issue 4/2012

Login to get access

Abstract

Introduction

Community-acquired pneumonia (CAP) account for a high proportion of ICU admissions, with Streptococcus pneumoniae being the main pathogen responsible for these infections. However, little is known on the clinical features and outcomes of ICU patients with pneumococcal pneumonia. The aims of this study were to provide epidemiological data and to determine risk factors of mortality in patients admitted to ICU for severe S. pneumoniae CAP.

Methods

We performed a retrospective review of two prospectively-acquired multicentre ICU databases (2001-2008). Patients admitted for management of severe pneumococcal CAP were enrolled if they met the 2001 American Thoracic Society criteria for severe pneumonia, had life-threatening organ failure and had a positive microbiological sample for S. pneumoniae. Patients with bronchitis, aspiration pneumonia or with non-pulmonary pneumococcal infections were excluded.

Results

Two hundred and twenty two patients were included, with a median SAPS II score reaching 47 [36-64]. Acute respiratory failure (n = 154) and septic shock (n = 54) were their most frequent causes of ICU admission. Septic shock occurred in 170 patients (77%) and mechanical ventilation was required in 186 patients (84%); renal replacement therapy was initiated in 70 patients (32%). Bacteraemia was diagnosed in 101 patients. The prevalence of S. pneumoniae strains with decreased susceptibility to penicillin was 39.7%. Although antibiotherapy was adequate in 92.3% of cases, hospital mortality reached 28.8%. In multivariate analysis, independent risk factors for mortality were age (OR 1.05 (95% CI: 1.02-1.08)), male sex (OR 2.83 (95% CI: 1.16-6.91)) and renal replacement therapy (OR 3.78 (95% CI: 1.71-8.36)). Co-morbidities, macrolide administration, concomitant bacteremia or penicillin susceptibility did not influence outcome.

Conclusions

In ICU, mortality of pneumococcal CAP remains high despite adequate antimicrobial treatment. Baseline demographic data and renal replacement therapy have a major impact on adverse outcome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shah SS, Ratner AJ: Trends in invasive pneumococcal disease-associated hospitalizations. Clin Infect Dis. 2006, 42: e1-5. 10.1086/498745.PubMedCrossRef Shah SS, Ratner AJ: Trends in invasive pneumococcal disease-associated hospitalizations. Clin Infect Dis. 2006, 42: e1-5. 10.1086/498745.PubMedCrossRef
2.
go back to reference Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG: Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA. 2001, 285: 1729-1735. 10.1001/jama.285.13.1729.PubMedCrossRef Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG: Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA. 2001, 285: 1729-1735. 10.1001/jama.285.13.1729.PubMedCrossRef
3.
go back to reference Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.PubMedCrossRef Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.PubMedCrossRef
4.
go back to reference Marrie TJ, Shariatzadeh MR: Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore). 2007, 86: 103-111. 10.1097/MD.0b013e3180421c16.CrossRef Marrie TJ, Shariatzadeh MR: Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore). 2007, 86: 103-111. 10.1097/MD.0b013e3180421c16.CrossRef
5.
go back to reference Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC: The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010, 36: 222-231. 10.1007/s00134-009-1738-3.PubMedPubMedCentralCrossRef Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC: The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010, 36: 222-231. 10.1007/s00134-009-1738-3.PubMedPubMedCentralCrossRef
6.
go back to reference Bordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, Venero Mdel C, Ramirez J: Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest. 2010, 138: 279-283. 10.1378/chest.09-2702.PubMedCrossRef Bordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, Venero Mdel C, Ramirez J: Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest. 2010, 138: 279-283. 10.1378/chest.09-2702.PubMedCrossRef
7.
go back to reference File TM, Marrie TJ: Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010, 122: 130-141. 10.3810/pgm.2010.03.2130.PubMedCrossRef File TM, Marrie TJ: Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010, 122: 130-141. 10.3810/pgm.2010.03.2130.PubMedCrossRef
8.
go back to reference Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J: Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010, 36: 612-620. 10.1007/s00134-009-1730-y.PubMedCrossRef Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J: Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010, 36: 612-620. 10.1007/s00134-009-1730-y.PubMedCrossRef
9.
go back to reference Georges H, Leroy O, Vandenbussche C, Guery B, Alfandari S, Tronchon L, Beaucaire G: Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med. 1999, 25: 198-206. 10.1007/s001340050816.PubMedCrossRef Georges H, Leroy O, Vandenbussche C, Guery B, Alfandari S, Tronchon L, Beaucaire G: Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med. 1999, 25: 198-206. 10.1007/s001340050816.PubMedCrossRef
10.
go back to reference Moine P, Vercken JB, Chevret S, Gajdos P: Severe community-acquired pneumococcal pneumonia. The French Study Group of Community-Acquired Pneumonia in ICU. Scand J Infect Dis. 1995, 27: 201-206. 10.3109/00365549509019009.PubMedCrossRef Moine P, Vercken JB, Chevret S, Gajdos P: Severe community-acquired pneumococcal pneumonia. The French Study Group of Community-Acquired Pneumonia in ICU. Scand J Infect Dis. 1995, 27: 201-206. 10.3109/00365549509019009.PubMedCrossRef
11.
go back to reference Wunderink RG: Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med. 2009, 30: 146-153. 10.1055/s-0029-1202933.PubMedCrossRef Wunderink RG: Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med. 2009, 30: 146-153. 10.1055/s-0029-1202933.PubMedCrossRef
12.
go back to reference Van der Poll T, Opal SM: Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009, 374: 1543-1556. 10.1016/S0140-6736(09)61114-4.PubMedCrossRef Van der Poll T, Opal SM: Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009, 374: 1543-1556. 10.1016/S0140-6736(09)61114-4.PubMedCrossRef
13.
go back to reference Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001, 163: 1730-1754.PubMedCrossRef Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001, 163: 1730-1754.PubMedCrossRef
14.
go back to reference Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A: Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med. 1998, 158: 1102-1108.PubMedCrossRef Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A: Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med. 1998, 158: 1102-1108.PubMedCrossRef
15.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest. 2009, 136: e28-10.1378/chest.09-2267.PubMedCrossRef Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest. 2009, 136: e28-10.1378/chest.09-2267.PubMedCrossRef
16.
go back to reference Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994, 149: 818-824.PubMedCrossRef Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994, 149: 818-824.PubMedCrossRef
17.
go back to reference Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004, 8: R204-212. 10.1186/cc2872.PubMedPubMedCentralCrossRef Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004, 8: R204-212. 10.1186/cc2872.PubMedPubMedCentralCrossRef
18.
go back to reference Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D: The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA. 1996, 276: 802-810. 10.1001/jama.1996.03540100046027.PubMedCrossRef Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D: The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA. 1996, 276: 802-810. 10.1001/jama.1996.03540100046027.PubMedCrossRef
19.
go back to reference Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993, 270: 2957-2963. 10.1001/jama.1993.03510240069035.PubMedCrossRef Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993, 270: 2957-2963. 10.1001/jama.1993.03510240069035.PubMedCrossRef
21.
go back to reference Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF: Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000, 342: 681-689. 10.1056/NEJM200003093421002.PubMedCrossRef Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF: Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000, 342: 681-689. 10.1056/NEJM200003093421002.PubMedCrossRef
22.
24.
go back to reference Rodriguez A, Lisboa T, Blot S, Martin-Loeches I, Sole-Violan J, De Mendoza D, Rello J: Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med. 2009, 35: 430-438. 10.1007/s00134-008-1363-6.PubMedCrossRef Rodriguez A, Lisboa T, Blot S, Martin-Loeches I, Sole-Violan J, De Mendoza D, Rello J: Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med. 2009, 35: 430-438. 10.1007/s00134-008-1363-6.PubMedCrossRef
25.
go back to reference Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Diaz V, Verdaguer R, Dorca J, Manresa F, Gudiol F: Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008, 32: 733-739. 10.1183/09031936.00128107.PubMedCrossRef Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Diaz V, Verdaguer R, Dorca J, Manresa F, Gudiol F: Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J. 2008, 32: 733-739. 10.1183/09031936.00128107.PubMedCrossRef
26.
go back to reference Marrie TJ, Low DE, De Carolis E: A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology--results from a Canadian multicentre study. Can Respir J. 2003, 10: 368-374.PubMed Marrie TJ, Low DE, De Carolis E: A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology--results from a Canadian multicentre study. Can Respir J. 2003, 10: 368-374.PubMed
27.
go back to reference Bordon J, Peyrani P, Brock GN, Blasi F, Rello J, File T, Ramirez J: The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest. 2008, 133: 618-624. 10.1378/chest.07-1322.PubMedCrossRef Bordon J, Peyrani P, Brock GN, Blasi F, Rello J, File T, Ramirez J: The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest. 2008, 133: 618-624. 10.1378/chest.07-1322.PubMedCrossRef
28.
go back to reference Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007, 44 (Suppl 2): S27-72.PubMedCrossRef Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007, 44 (Suppl 2): S27-72.PubMedCrossRef
29.
go back to reference Garcia-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Linares J, Gudiol F, Carratala J: Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax. 2010, 65: 77-81. 10.1136/thx.2009.123612.PubMedCrossRef Garcia-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Linares J, Gudiol F, Carratala J: Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax. 2010, 65: 77-81. 10.1136/thx.2009.123612.PubMedCrossRef
30.
go back to reference Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med. 2005, 33: 952-961. 10.1097/01.CCM.0000162381.24074.D7.PubMedCrossRef Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med. 2005, 33: 952-961. 10.1097/01.CCM.0000162381.24074.D7.PubMedCrossRef
32.
go back to reference Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S: Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2011, 183: 1561-1568. 10.1164/rccm.201007-1167OC.PubMedCrossRef Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S: Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2011, 183: 1561-1568. 10.1164/rccm.201007-1167OC.PubMedCrossRef
33.
go back to reference Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005, 171: 242-248.PubMedCrossRef Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005, 171: 242-248.PubMedCrossRef
34.
go back to reference Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG: Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010, 181: 975-982. 10.1164/rccm.200905-0808OC.PubMedCrossRef Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG: Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010, 181: 975-982. 10.1164/rccm.200905-0808OC.PubMedCrossRef
35.
go back to reference Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J: Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008, 358: 111-124. 10.1056/NEJMoa071366.PubMedCrossRef Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J: Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008, 358: 111-124. 10.1056/NEJMoa071366.PubMedCrossRef
36.
go back to reference Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N: Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother. 2009, 63: 1025-1033. 10.1093/jac/dkp088.PubMedCrossRef Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttorp N: Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother. 2009, 63: 1025-1033. 10.1093/jac/dkp088.PubMedCrossRef
37.
go back to reference Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J: Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003, 36: 389-395. 10.1086/367541.PubMedCrossRef Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J: Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003, 36: 389-395. 10.1086/367541.PubMedCrossRef
38.
go back to reference Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001, 161: 1837-1842. 10.1001/archinte.161.15.1837.PubMedCrossRef Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001, 161: 1837-1842. 10.1001/archinte.161.15.1837.PubMedCrossRef
39.
go back to reference Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R, Gregoire P, Legare M, Nepveu F, Thibert D, Tremblay C, Tremblay J: Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J. 2004, 11: 589-593.PubMed Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R, Gregoire P, Legare M, Nepveu F, Thibert D, Tremblay C, Tremblay J: Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J. 2004, 11: 589-593.PubMed
40.
go back to reference Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004, 170: 440-444. 10.1164/rccm.200311-1578OC.PubMedCrossRef Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004, 170: 440-444. 10.1164/rccm.200311-1578OC.PubMedCrossRef
41.
go back to reference Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, Rello J: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007, 35: 1493-1498. 10.1097/01.CCM.0000266755.75844.05.PubMedCrossRef Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, Rello J: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007, 35: 1493-1498. 10.1097/01.CCM.0000266755.75844.05.PubMedCrossRef
42.
go back to reference Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009, 33: 153-159. 10.1183/09031936.00054108.PubMedCrossRef Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009, 33: 153-159. 10.1183/09031936.00054108.PubMedCrossRef
43.
go back to reference Chokshi R, Restrepo MI, Weeratunge N, Frei CR, Anzueto A, Mortensen EM: Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2007, 26: 447-451. 10.1007/s10096-007-0307-3.PubMedCrossRef Chokshi R, Restrepo MI, Weeratunge N, Frei CR, Anzueto A, Mortensen EM: Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2007, 26: 447-451. 10.1007/s10096-007-0307-3.PubMedCrossRef
44.
go back to reference Dwyer R, Ortqvist A, Aufwerber E, Henriques Normark B, Marrie TJ, Mufson MA, Torres A, Woodhead MA, Alenius M, Kalin M: Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006, 25: 518-521. 10.1007/s10096-006-0183-2.PubMedCrossRef Dwyer R, Ortqvist A, Aufwerber E, Henriques Normark B, Marrie TJ, Mufson MA, Torres A, Woodhead MA, Alenius M, Kalin M: Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006, 25: 518-521. 10.1007/s10096-006-0183-2.PubMedCrossRef
45.
go back to reference Aspa J, Rajas O, Rodriguez de Castro F, Huertas MC, Borderias L, Cabello FJ, Tabara J, Hernandez-Flix S, Martinez-Sanchis A, Torres A: Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J. 2006, 27: 1010-1019.PubMed Aspa J, Rajas O, Rodriguez de Castro F, Huertas MC, Borderias L, Cabello FJ, Tabara J, Hernandez-Flix S, Martinez-Sanchis A, Torres A: Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J. 2006, 27: 1010-1019.PubMed
46.
go back to reference Burgess DS, Lewis JS: Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther. 2000, 22: 872-878. 10.1016/S0149-2918(00)80059-4.PubMedCrossRef Burgess DS, Lewis JS: Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther. 2000, 22: 872-878. 10.1016/S0149-2918(00)80059-4.PubMedCrossRef
47.
go back to reference Paul M, Nielsen AD, Gafter-Gvili A, Tacconelli E, Andreassen S, Almanasreh N, Goldberg E, Cauda R, Frank U, Leibovici L: The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J. 2007, 30: 525-531. 10.1183/09031936.00031007.PubMedCrossRef Paul M, Nielsen AD, Gafter-Gvili A, Tacconelli E, Andreassen S, Almanasreh N, Goldberg E, Cauda R, Frank U, Leibovici L: The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J. 2007, 30: 525-531. 10.1183/09031936.00031007.PubMedCrossRef
48.
go back to reference Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D: Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis. 2005, 24: 688-690. 10.1007/s10096-005-0018-6.PubMedCrossRef Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D: Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis. 2005, 24: 688-690. 10.1007/s10096-005-0018-6.PubMedCrossRef
49.
go back to reference Dowell SF, Whitney CG, Wright C, Rose CE, Schuchat A: Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis. 2003, 9: 573-579. 10.3201/eid0905.020556.PubMedCrossRef Dowell SF, Whitney CG, Wright C, Rose CE, Schuchat A: Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis. 2003, 9: 573-579. 10.3201/eid0905.020556.PubMedCrossRef
50.
go back to reference Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, Schaffner W, Craig AS, Griffin MR: Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med. 2005, 118: 285-291. 10.1016/j.amjmed.2004.09.016.PubMedCrossRef Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, Schaffner W, Craig AS, Griffin MR: Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med. 2005, 118: 285-291. 10.1016/j.amjmed.2004.09.016.PubMedCrossRef
51.
go back to reference Recent trends in antimicrobial resistance among Streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience. Euro Surveill. 2008, pii: 19035 Recent trends in antimicrobial resistance among Streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience. Euro Surveill. 2008, pii: 19035
52.
go back to reference Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995, 333: 474-480. 10.1056/NEJM199508243330802.PubMedCrossRef Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995, 333: 474-480. 10.1056/NEJM199508243330802.PubMedCrossRef
53.
go back to reference Aspa J, Rajas O, Rodriguez de Castro F, Blanquer J, Zalacain R, Fenoll A, de Celis R, Vargas A, Rodriguez Salvanes F, Espana PP, Rello J, Torres A: Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis. 2004, 38: 787-798. 10.1086/381886.PubMedCrossRef Aspa J, Rajas O, Rodriguez de Castro F, Blanquer J, Zalacain R, Fenoll A, de Celis R, Vargas A, Rodriguez Salvanes F, Espana PP, Rello J, Torres A: Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis. 2004, 38: 787-798. 10.1086/381886.PubMedCrossRef
54.
go back to reference Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9.PubMedCrossRef Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9.PubMedCrossRef
55.
go back to reference Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, Lim TK: Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. 2009, 64: 598-603. 10.1136/thx.2009.113795.PubMedCrossRef Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, Lim TK: Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. 2009, 64: 598-603. 10.1136/thx.2009.113795.PubMedCrossRef
56.
go back to reference Lujan M, Gallego M, Belmonte Y, Fontanals D, Valles J, Lisboa T, Rello J: Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J. 2010, 36: 1073-1079. 10.1183/09031936.00176309.PubMedCrossRef Lujan M, Gallego M, Belmonte Y, Fontanals D, Valles J, Lisboa T, Rello J: Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J. 2010, 36: 1073-1079. 10.1183/09031936.00176309.PubMedCrossRef
57.
go back to reference Mira JP, Max A, Burgel PR: The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care. 2008, 12 (Suppl 6): S5-10.1186/cc7028.PubMedPubMedCentralCrossRef Mira JP, Max A, Burgel PR: The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care. 2008, 12 (Suppl 6): S5-10.1186/cc7028.PubMedPubMedCentralCrossRef
58.
go back to reference Brouwer MC, de Gans J, Heckenberg SG, Zwinderman AH, van der Poll T, van de Beek D: Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis. 2009, 9: 31-44. 10.1016/S1473-3099(08)70261-5.PubMedCrossRef Brouwer MC, de Gans J, Heckenberg SG, Zwinderman AH, van der Poll T, van de Beek D: Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis. 2009, 9: 31-44. 10.1016/S1473-3099(08)70261-5.PubMedCrossRef
Metadata
Title
Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study
Authors
Nicolas Mongardon
Adeline Max
Adrien Bouglé
Frédéric Pène
Virginie Lemiale
Julien Charpentier
Alain Cariou
Jean-Daniel Chiche
Jean-Pierre Bedos
Jean-Paul Mira
Publication date
01-08-2012
Publisher
BioMed Central
Published in
Critical Care / Issue 4/2012
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc11471

Other articles of this Issue 4/2012

Critical Care 4/2012 Go to the issue